New CytoSure Microarray for Cancer Research
23 Apr 2013In this video Spencer Howell discusses the new CytoSure Cancer +SNP array available from Oxford Gene Technology (OGT) for the superior detection of copy number variation and loss of heterozygosity on a single array. Spencer tells SelectScience more about the CytoSure product range and explains how in addition to offering gene-focused arrays the company also provides custom arrays. Spencer also discusses the company’s software solutions for interpreting microarray and next generation sequencing data. Interview filmed by SelectScience at AACR 2013.
About the company
Oxford Gene Technology Ltd
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) is focused on providing innovative genetics research and biomarker solutions to advance molecular medicine.
The company has three core commercial arms: Genomics, Biomarkers and Licensing. In addition, an Exploratory Research division, headed by Professor Southern, focuses on developing new diagnostic techniques with potential for in-house commercialisation or partnering with diagnostic and pharmaceutical organisations.
With its clear strategic focus, OGT has invested significantly in highly qualified expertise, doubling the workforce over the last 2 years to over 60 people. In anticipation of this rapid expansion, OGT moved to a new, purpose-built facility located in the Begbroke Science Park near Oxford, UK. These strategic decisions have resulted in strong year-on-year revenue growth across all business units. The company plans further expansion fuelled by growth into the clinical research market, a full pipeline of new products and further corporate development opportunities.
OGT’s highly experienced management team are driving this growth through end-user sales and by forging strong relationships with major international corporations including Agilent, Illumina and Roche.
Related products
Request Quote for All Products
CytoSure™ Cancer +SNP Array
Oxford Gene Technology LtdReliable detection of copy number changes and loss of heterozygosity on a single array for haematological malignancies and solid cancers. The CytoSure Cancer +SNP array delivers: ■ Flexible choice of reference sample ■ Confident detection of CNV and LOH on a single array ■ An optimised design allowing identification of key genomic aberrations ■ Cancer-specific tracks enabling fast and easy data generation and interpretation of cytogenetic results
